ABSTRACTS
Abstract Submission Deadline
14 FEBRUARY, 2023 28 FEBRUARY, 2023 NEW EXTENDED DEADLINE
Submissions
- All abstracts must be submitted to the Secretariat via e-mail by the deadline. After you sent your abstract, you should receive an e-mail from the office within 5 days confirming receipt. If you do not receive an e-mail, please contact us. Secretariat e-mail address: isid2023spp@gmail.com
- Changes to abstract title or abstract text, as well as additions or deletions of author names, will NOT be permitted after submission. Proofread your abstract to identify and correct any errors before submission.
- Submission of an abstract constitutes a commitment by the author(s) to present their work if the abstract is accepted. Authors of accepted abstracts are expected to register for the symposium and pay the registration fee.
Abstract guidelines
- There is a limit of 2,300 characters for the text of your abstract submission (title, authors, institutions, abstract body, and all spaces will be counted).
- Abstracts must be submitted as a PDF document. Other formats will not be accepted.
- After the abstract submission deadline, all abstracts will be reviewed by the Organizing Committee.
- Notification of the status of abstracts will be sent electronically to the official contact and presenter in early April, 2023.
- All accepted abstracts will be poster presentations. Some of the abstracts will be selected as oral presentations. Poster presenters will be required to bring a hard copy of their poster for display in the Poster Hall and participate in their assigned Poster sessions.
Abstract outcomes
Poster Number | 1st author | Affiliation | title | outcomes |
1 | Henriette Franz | Department of Biomedicine, University of Basel, Pestalozzistrasse 20, 4056 Basel | CRISPR/Cas9 screening identified KLF5 as novel modulator of desmosomal adhesion in pemphigus | Oral & Poster |
2 | Takenobu Yamamoto | Department of Dermatology, Kawasaki Medical School, Kurashiki, Japan | Disturbed epithelial integrity protects against cell-to-cell transmission of HSV-1 in keratinocytes | Poster |
3 | Navaneetha Krishnan Bharathan | Dept of Dermatology, Penn State College of Medicine, Hershey, USA | Structure of a novel endoplasmic reticulum-desmosome complex | Oral & Poster |
4 | Nina Kokkonen | Department of Dermatology, Research Unit of Clinical Science, University of Oulu, Finland | Structural disruption of collagen XVII/BP180 decelerates the cutaneous wound closure in mice | Poster |
5 | Anna M. Sigmund | Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, LMU Munich, Germany | EPAC1 contributes to apremilast-mediated rescue of pemphigus autoantibody-induced loss of keratinocyte adhesion | Poster |
6 | Siavash Rahimi | Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Switzerland | Role of proliferation and mechanostructural signaling in pemphigus vulgaris | Poster |
7 | William V.J. Hariton | Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Switzerland | Uncoupling desmosomal cadherin adhesion activates quiescent hair follicle stem cells and orchestrates self-organized regeneration through outside-in signaling | Poster |
8 | William V.J. Hariton | Department of Dermatology, Bern University Hospital, Switzerland; Department for BioMedical Research, University of Bern, Switzerland | To enhance wound healing through non-invasive biophysical applications | Poster |
9 | Wenxiu He | Department of Oral Medicine, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases, Beijing, PR China | Saliva antibodies to desmoglein 3 as a diagnostic and disease monitoring marker in mucosal pemphigus vlgaris | Poster |
10 | Julia Haneberg | Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, LMU Munich, Munich, Germany | The role of PKC subtype-specific signaling in the regulation of keratinocyte adhesion in pemphigus | Poster |
11 | Roberta Lotti | DermoLAb, University of Modena and Reggio Emilia, Modena, Italy. | Blocking Fas Ligand ameliorates pemphigus: PC111 efficacy in in-vitro, ex-vivo and in-vivo human pemphigus models | Poster |
12 | Kristina Seiffert-Sinha | Dept. of Dermatology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA | CyTOF technology reveals an HLA-dependent pro-inflammatory immunome in pemphigus through shifts in dendritic-, natural killer- and T cell compartments | Poster |
13 | Lauren Sielski | Dept. of Dermatology, University at Buffalo | Desmoglein compensation hypothesis fidelity assessment in Pemphigus | Poster |
14 | Animesh A. Sinha | Dept. of Dermatology, Jacobs School of Medicine and Biomedical Sciences, University at | Patient Genetics Shape the Autoimmune Response in Pemphigus Vulgaris | Poster |
15 | Takuya Kawamura | Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University | Basophil activation and low levels of circulating basophils correlate with clinical severity in bullous pemphigoid | Poster |
16 | Joost Meijer | University of Groningen, University Medical Center Groningen, Department of Dermatology, UMCG | Gene expression profiling points to complement activation as important for blister formation in bullous pemphigoid | Poster |
17 | Shoko Mai | Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan | Conformational epitope mapping of autoantibodies against BP180 in dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid | Oral & Poster |
18 | Chihiro Shiiya | Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan | Aged mice produce IgM autoantibodies against the basement membrane zone | Poster |
19 | Jing Li | Division of Dermatology, Rush University Medical Center, Chicago, Illinois, USA | Afucosylated anti-IL5Rα antibody is an effective treatment in murine bullous pemphigoid-like epidermolysis bullosa | Poster |
20 | Manuela Pigors | Lübeck Institute of Experimental Dermatology; University of Lübeck, Germany | The pathogenicity of bullous pemphigoid anti-type XVII collagen C-terminal IgG is driven by complement and Fcγ receptor-mediated mechanisms | Poster |
21 | Stephanie Goletz | Lübeck Institute of Experimental Dermatology, University of Lübeck, Germany | Laminin beta4: a protein of the cutaneous basal membrane zone and autoantigen of anti-p200 pemphigoid | Oral & Poster |
22 | S. Patzelt | Lübeck Institute of Experimental Dermatology; University of Lübeck, Germany | CXCR1/2 inhibition ameliorates clinical lesions in experimental mucous membrane pemphigoid | Poster |
23 | Katja Bieber | Luebeck institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany | Selective inhibition of c-Met as a novel treatment option in experimental epidermolysis bullosa acquisita | Poster |
24 | Norito ishii | Department of Dermatology, Kurume University School of Medicine, Kurume, Fukuoka, Japan, | Concomitant mucous membrane pemphigoid and dermatitis herpetiformis: Analysis of the autoimmune blistering response | Poster |
25 | Janet A. Fairley | 1University of Iowa, Iowa City, IA, USA | Design of A Phase 3 Study of Benralizumab in Bullous Pemphigoid (FJORD) | Poster |
26 | Simon D. Lytton | SeraDiaLogistics 81545 Munich, Germany | Novel Autoantigen Peptide Epitopes as Theranostic Targets in Incurable Autoimmune Blistering Diseases | Poster |
27 | Natalie Gross | Luebeck Institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany | Adoptive Treg transfer ameliorates autoantibody-induced inflammation in experimental EBA | Poster |
28 | Norihiro Yoshimoto | Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan | Type XVII collagen-specific CD4+ T cell clones induce bullous pemphigoid in mice by producing IL-5 | Poster |
29 | Miho Mukai | Dermatology, Keio University School of Medicine, Tokyo | A novel therapeutic strategy using stabilized antigen-specific iTreg for pemphigus | Poster |
30 | Shirin Emtenani | Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany | Characterization and pharmacological inhibition of an adult antibody-transfer mouse model of pemphigus vulgaris | Poster |
31 | Beatriz Wittlin | argenx, Ghent, Belgium | Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases | Poster |
32 | Baptiste Janela | Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore | Deciphering the immune mechanism of autoreactive B cells in Pemphigus | Oral & Poster |
33 | Shohei Egami | Department of Dermatology, Keio University School of Medicine, | Desmoglein-specific B-cell-targeted single-cell analysis revealing unique gene regulation in pemphigus patients | Poster |
34 | Sho Katayama | Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan | NUDT15 variants among Japanese patients with autoimmune blistering diseases: a single-center retrospective observational study | Poster |
35 | Hetal Patel | Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA | Quality of life in patients with bullous pemphigoid | Poster |
36 | Khalaf Kridin | Azrieli Faculty of Medicine, Bar-Ilan University, Safed, ISR | A Retrospective Observational Study to Assess the Risk of Select Adverse Events of Special Interest During Oral Corticosteroid Use in Bullous Pemphigoid Patients | Poster |
37 | Päivi Leisti | Medical Research Center Oulu, Oulun yliopistollinen sairaala, Oulu, Finland | MUCOUS MEMBRANE PEMPHIGOID IS ASSOCIATED WITH MULTIPLE SOMATIC AND PSYCHIATRIC COMORBIDITIES | Poster |
38 | Outi Varpuluoma | PEDEGO Research Unit, University of Oulu, Oulu, Finland; | Solid and hematological malignancies are not associated with increased risk for bullous pemphigoid in a national cohort of 3708 patients | Poster |
39 | Nina van Beek | Department of Dermatology, Allergology and Venereology, University of Lübeck, Lübeck, Germany | Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomised controlled trial | Poster |
40 | Calvin N. Ho | AstraZeneca, Gaithersburg, MD, USA | Qualitative Patient Interviews to Explore Health-Related Quality of Life in Patients with Bullous Pemphigoid | Poster |
41 | Nirohshah Trialonis-Suthakharan | Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany | Patient-reported impact of dermatological diseases (PRIDD) measure: pemphigus and pemphigoid delphi data | Poster |